scispace - formally typeset
F

Francisco Pozo

Researcher at Carlos III Health Institute

Publications -  138
Citations -  4419

Francisco Pozo is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Influenza vaccine & Vaccination. The author has an hindex of 33, co-authored 122 publications receiving 3854 citations. Previous affiliations of Francisco Pozo include World Health Organization.

Papers
More filters
Journal ArticleDOI

First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020

TL;DR: In the WHO European Region, COVID-19 surveillance was implemented 27 January 2020, and the first European cases are detailed, with among 38 cases studied, 21 were linked to two clusters in Germany and France, 14 were infected in China.
Journal ArticleDOI

Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome.

TL;DR: A large series of patients with chronic obstructive pulmonary disease and probable invasive pulmonary aspergillosis (IPA) are described, and the risk factors and incidence of the disease in patients with isolation of Aspergillus from lower respiratory tract samples are described.
Journal ArticleDOI

Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study.

TL;DR: The clinical impact of other viruses different from the respiratory syncytial virus (RSV) in hospitalized infants with bronchiolitis is described.
Journal ArticleDOI

Diagnostic system for rapid and sensitive differential detection of pathogens

TL;DR: A diagnostic system for rapid, sensitive, multiplex discrimination of microbial gene sequences and its application for detecting 22 respiratory pathogens in clinical samples is described.
Journal ArticleDOI

Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12.

TL;DR: A low preventive effect of the 2011/12 seasonal influenza vaccine is suggested, and a decline in VE with time since vaccination, mainly affected people aged 65 or over.